Pfizer’s (PFE) “Overweight” Rating Reaffirmed at Cantor Fitzgerald

Cantor Fitzgerald restated their overweight rating on shares of Pfizer (NYSE:PFE – Free Report) in a research report report published on Monday morning, Benzinga reports. The brokerage currently has a $45.00 price target on the biopharmaceutical company’s stock. PFE has been the topic of several other research reports. StockNews.com upgraded Pfizer from a hold rating […]

Leave a Reply

Your email address will not be published.

Previous post Needham & Company LLC Reiterates Buy Rating for PROS (NYSE:PRO)
Next post Royal Bank of Canada Cuts Osisko Gold Royalties (NYSE:OR) Price Target to $20.00